Investment analysts at Citigroup initiated coverage on shares of Teladoc (NYSE:TDOC) in a report released on Thursday, The Fly reports. The brokerage set a “buy” rating on the health services provider’s stock.
A number of other equities analysts have also recently weighed in on TDOC. Cowen reaffirmed an “outperform” rating and set a $39.00 price target on shares of Teladoc in a research note on Saturday, September 30th. Piper Jaffray Companies reissued a “buy” rating and issued a $42.00 price objective on shares of Teladoc in a research note on Friday, September 29th. Cantor Fitzgerald reissued a “hold” rating and issued a $31.00 price objective on shares of Teladoc in a research note on Tuesday, September 26th. ValuEngine upgraded shares of Teladoc from a “sell” rating to a “hold” rating in a report on Sunday. Finally, Zacks Investment Research upgraded shares of Teladoc from a “sell” rating to a “hold” rating in a report on Thursday, September 21st. One investment analyst has rated the stock with a sell rating, five have issued a hold rating and eleven have given a buy rating to the company. Teladoc has an average rating of “Buy” and a consensus target price of $39.15.
Teladoc (NYSE TDOC) opened at $36.85 on Thursday. The company has a debt-to-equity ratio of 0.83, a quick ratio of 5.08 and a current ratio of 5.08. Teladoc has a 12 month low of $15.65 and a 12 month high of $37.90. The firm has a market cap of $2,065.19, a price-to-earnings ratio of -25.59 and a beta of 0.42.
Teladoc (NYSE:TDOC) last posted its quarterly earnings results on Wednesday, November 1st. The health services provider reported ($0.55) earnings per share for the quarter, missing the Zacks’ consensus estimate of ($0.30) by ($0.25). Teladoc had a negative return on equity of 21.59% and a negative net margin of 39.61%. The company had revenue of $68.70 million for the quarter, compared to analyst estimates of $67.53 million. During the same period last year, the company earned ($0.33) earnings per share. The business’s revenue for the quarter was up 112.0% compared to the same quarter last year. research analysts predict that Teladoc will post -1.56 earnings per share for the current year.
In related news, CEO Jason N. Gorevic sold 20,000 shares of the firm’s stock in a transaction that occurred on Thursday, November 2nd. The shares were sold at an average price of $32.10, for a total value of $642,000.00. Following the transaction, the chief executive officer now owns 838,261 shares in the company, valued at $26,908,178.10. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available at this link. Also, CEO Jason N. Gorevic sold 100,000 shares of the firm’s stock in a transaction that occurred on Monday, December 4th. The shares were sold at an average price of $32.99, for a total transaction of $3,299,000.00. Following the completion of the transaction, the chief executive officer now owns 718,261 shares in the company, valued at approximately $23,695,430.39. The disclosure for this sale can be found here. Insiders sold 210,000 shares of company stock worth $6,889,350 in the last 90 days. 4.47% of the stock is currently owned by insiders.
A number of hedge funds and other institutional investors have recently bought and sold shares of TDOC. Iguana Healthcare Management LLC acquired a new stake in Teladoc in the third quarter valued at approximately $1,160,000. Neuberger Berman Group LLC grew its position in Teladoc by 53.4% in the third quarter. Neuberger Berman Group LLC now owns 25,785 shares of the health services provider’s stock valued at $855,000 after acquiring an additional 8,971 shares in the last quarter. California Public Employees Retirement System grew its position in Teladoc by 52.1% in the third quarter. California Public Employees Retirement System now owns 11,409 shares of the health services provider’s stock valued at $378,000 after acquiring an additional 3,909 shares in the last quarter. Bamco Inc. NY grew its position in Teladoc by 751.9% in the third quarter. Bamco Inc. NY now owns 1,455,900 shares of the health services provider’s stock valued at $48,263,000 after acquiring an additional 1,285,000 shares in the last quarter. Finally, Granahan Investment Management Inc. MA acquired a new stake in Teladoc in the third quarter valued at approximately $14,569,000.
Teladoc Company Profile
Teladoc, Inc is a telehealth company. The Company offers telehealth platform, delivering on-demand healthcare anytime, anywhere, through mobile devices, the Internet, video and phone. The Company’s solution connects its Members, with its over 3,000 board certified physicians and behavioral health professionals treating a range of conditions and cases from acute diagnoses, such as upper respiratory infection, urinary tract infection and sinusitis to dermatological conditions, anxiety and smoking cessation.